SLC5A2 and Abdominal obesity: An unadjusted univariate linear regression analysis showed that the BMI at the baseline (p = 0.046) and relative changes (Δ) of LVEF (p = 0.040), LAVI (p = 0.001), LVMMI (p = 0.012), E/e’ (p = 0.001), NYHA class (p = 0.042), and NT-proBNP (p = 0.012) were significantly associated with the adropin levels during SGLT2 inhibitor dapagliflozin administration, whereas age, abdominal obesity, and ΔBMI were not.